Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.66M | 8.23M | 1.33M | 29.57M | 7.89M |
Gross Profit | 1.51M | 7.87M | 1.12M | 29.40M | 7.89M |
EBITDA | -24.35M | -23.06M | -29.46M | -449.00K | -17.93M |
Net Income | -34.35M | -32.48M | -34.07M | 376.00K | -18.03M |
Balance Sheet | |||||
Total Assets | 25.13M | 34.02M | 51.30M | 42.90M | 19.32M |
Cash, Cash Equivalents and Short-Term Investments | 20.02M | 28.92M | 48.26M | 30.44M | 17.29M |
Total Debt | 703.00K | 43.00M | 1.28M | 675.00K | 1.98M |
Total Liabilities | 63.98M | 49.93M | 40.70M | 4.93M | 10.56M |
Stockholders Equity | -38.85M | -15.91M | 10.61M | 37.98M | 8.76M |
Cash Flow | |||||
Free Cash Flow | -25.68M | -19.91M | -13.61M | -10.73M | -13.18M |
Operating Cash Flow | -24.70M | -18.14M | -13.37M | -10.73M | -13.12M |
Investing Cash Flow | -638.00K | -1.78M | -246.00K | 0.00 | -55.00K |
Financing Cash Flow | 16.44M | 414.00K | 31.33M | 23.78M | 7.87M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | CHF27.37B | 16.73 | 9.37% | 1.98% | 28.68% | 7.54% | |
44 Neutral | $93.75M | ― | -55.14% | ― | -99.43% | -69.40% | |
44 Neutral | $94.17M | ― | -122.69% | ― | ― | 20.91% | |
44 Neutral | $56.40M | ― | -127.99% | ― | ― | 37.54% | |
43 Neutral | $38.64M | ― | 91.63% | ― | -55.47% | 24.92% | |
35 Underperform | $47.32M | ― | -101.34% | ― | ― | 21.40% |
On July 17, 2025, Clearside Biomedical announced it is exploring strategic alternatives to enhance shareholder value, including the sale or license of assets, partnerships, or mergers. To conserve resources, all employees, including top executives, will transition to consulting roles, and internal R&D programs will be paused. The company has retained Piper Sandler to assist in this strategic evaluation process. This move comes amid challenging economic conditions and aims to advance Clearside’s proprietary suprachoroidal delivery platform and ophthalmology pipeline. The workforce reduction is expected to incur charges of approximately $3.4 million in the third quarter of 2025.
The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.
On May 30, 2025, Clearside Biomedical, Inc. held its annual meeting of stockholders where several key proposals were approved. The most significant outcome was the amendment to the company’s certificate of incorporation to increase the authorized shares of common stock from 200 million to 400 million, reflecting a strategic move to potentially expand its capital base. Additionally, the election of three directors, approval of executive compensation, and the ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025, were also confirmed.
The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.